niacinamide has been researched along with Carcinoma, Adenoid Cystic in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS." | 5.22 | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. ( Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G, 2016) |
| "Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity." | 2.80 | Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. ( Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomson, DJ | 1 |
| Silva, P | 1 |
| Denton, K | 1 |
| Bonington, S | 1 |
| Mak, SK | 1 |
| Swindell, R | 1 |
| Homer, J | 1 |
| Sykes, AJ | 1 |
| Lee, LW | 1 |
| Yap, BK | 1 |
| Slevin, NJ | 1 |
| Locati, LD | 1 |
| Perrone, F | 1 |
| Cortelazzi, B | 1 |
| Bergamini, C | 1 |
| Bossi, P | 1 |
| Civelli, E | 1 |
| Morosi, C | 1 |
| Lo Vullo, S | 1 |
| Imbimbo, M | 1 |
| Quattrone, P | 1 |
| Dagrada, GP | 1 |
| Granata, R | 1 |
| Resteghini, C | 1 |
| Mirabile, A | 1 |
| Alfieri, S | 1 |
| Orlandi, E | 1 |
| Mariani, L | 1 |
| Saibene, G | 1 |
| Pilotti, S | 1 |
| Licitra, L | 1 |
2 trials available for niacinamide and Carcinoma, Adenoid Cystic
| Article | Year |
|---|---|
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niac | 2015 |
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepider | 2016 |